Abstract
The p53 tumour suppressor protein inhibits malignant progression by mediating cell cycle arrest, apoptosis or repair following cellular stress. One of the major regulators of p53 function is the MDM2 protein, and multiple forms of cellular stress activate p53 by inhibiting the MDM2-mediated degradation of p53. Mutations in p53, or disruption of the pathways that allow activation of p53, seem to be a general feature of all cancers. Here we review recent advances in our understanding of the pathways that regulate p53 and the pathways that are induced by p53, as well as their implications for cancer therapy. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abrahamson JLA, Lee JM and Bernstein A (1995) Regulation of p53-mediated apoptosis and cell cycle arrest by steel factor. Mol Cell Biol 15: 6953–6960
Agarwal ML, Agarwal A, Taylor WR and Stark GR (1995) p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92: 8493–9497
Albrechtsen N, Dornreiter I, Grosse F, Kim E, Wiesmuller L and Deppert W (1999) Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene 18: 7706–7717
Almog N and Rotter V (1997) Involvement of p53 in cell differentiation and development. Biochem Biophys Acta 1333: F1–27
An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV and Neckers LM (1998) Stabilization of wild-type by hypoxia-inducible factor 1α. Nature 392: 405–408
Arriola EL, Rodriguez Lopez A and Chresta CM (1999) Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory loop. Oncogene 18: 1081–1091
Ashcroft M and Vousden KH (1999) Regulation of p53 stability. Oncogene 18: 7637–7643
Ashcroft M, Kubbutat MH and Vousden KH (1999) Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 19: 1751–1758
Ashcroft M, Taya Y and Vousden KH (2000) Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 20: 3224–3233
Ashkenazi A and Dixit VM (1998) Death receptors: Signaling and modulation. Science 281: 1305–1308
Atencio IA, Ramachandra M, Shabram P and Demers GW (2000) Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines. Cell Growth Differ 11: 247–253
Bachelder RE, Ribick MJ, Marchetti A, Falcioni R, Soddu S, Davis KR and Mercurio AM (1999) p53 inhibits alpha 6 beta 4 integrin signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. J Cell Biol 147: 1063–1072
Balint E, Bates S and Vousden KH (1999) Mdm2 binds p73α without targeting degradation. Oncogene 18: 3923–3929
Barak Y, Juven T, Haffner R and Oren M (1993) Mdm-2 expression is induced by wild type p53 activity. EMBO J 12: 461–468
Bates S, Phillips AC, Clarke PA, Stott F, Peters G, Ludwig RL and Vousden KH (1998a) p14ARF links the tumour suppressors RB and p53. Nature 395: 124–125
Bates S, Ryan KM, Phillips AC and Vousden KH (1998b) Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression. Oncogene 17: 1691–1703
Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE and Haber DA (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286: 2528–2531
Bennett M, Macdonald K, Chan S-W, Luzio JP and Simari R Weissberg (1998) Cell surface trafficking of Fas: a rapid mechanism of p53 mediated apoptosis. Science 282: 290–293
Blander G, Zalle N, Leal JF, Bar-Or RL, Yu CE and Oren M (2000) The Werner syndrome protein contributes to induction of p53 by DNA damage. FASEB J 14: 2138–2140
Blattner C, Tobiasch E, Litfen M, Rahmsdorf HJ and Herrlich P (1999) DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 18: 1723–1732
Bossy-Wetzel E and Green DR (1999) Apoptosis: checkpoint at the mitochondrial frontier. Mutat Res 434: 243–251
Böttger A, Böttger V, Sparks A, W-L L, Howard SF and Lane DP (1997) Design of a synthetic Mdm-2 binding mini protein that activates the p53 response in vivo. Current Biology 7: 860–869
Bouvet M, Ellis LM, Nishizaki M, Fujuwara T, Liu W, Bucana CD, Fang B, Lee JJ and Roth JA (1998) Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 58: 2288–2292
Boyd MT, Vlatkovic N and Haines DS (2000) A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2. J Biol Chem 275: 31883–31890
Boyd SD, Tsai KY and Jacks T (2000) An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nature Cell Biol 2: 563–568
Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T and Hannon GJ (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552–556
Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR and Kley N (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646–649
Butz K, Denk C, Ullmann A, Scheffner M and Hoppe-Seyler F (2000) Induction of apoptosis in human papillomavirus-positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 12: 6693–6697
Canman CE, Gilmer TM, Coutts SB and Kastan MB (1995) Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes and Dev 9: 600–611
Chan TA, Hermeking H, Lengauer C, Kinzler KW and Vogelstein B (1999) 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616–620
Chao C, Saito S, Kang J, Anderson CW, Appella E and Xu Y (2000) p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J 19: 4967–4975
Chehab NH, Malikzay A, Appel M and Halazonetis TD (2000) Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53. Genes and Dev 14: 278–288
Chen L, Lu W, Agrawal S, Zhou W, Zhang R and Chen J (1999) Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol Med 5: 21–34
Chen X, Ko LJ, Jayaraman L and Prives C (1996) p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes and Dev 10: 2438–2451
Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ and Vousden KH (1992) Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet 339: 1070–1073
Crook T, Marston NJ, Sara EA and Vousden KH (1994) Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79: 817–827
Damalas A, Ben-Ze'ev A, Simcha I, Shtutman M, Fernando J, Leal M, Zhurinsky J, Geiger B and Oren M (1999) Excess β-catenin promotes accumulation of transcriptionally active p53. EMBO J 18: 3054–3063
Dameron KM, Volpert OV, Tainsky MA and Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582–1584
Dobbelstein M, Wienzek S, Koenig S and Roth J (1999) Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 18: 2101–2106
Donehower LA (1996) The p53-deficient mouse: a model for basic and applied cancer studies. Sem Cancer Biol 7: 269–278
El-Deiry W, Tokino T, Velculescu VE, Levy DB, Parson VE, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) WAF1, a potential mediator of p53 tumour suppression. Cell 75: 817–825
Elenbaas B, Dobbelstein M, Roth J, Shenk T and Levine AJ (1996) The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med 2: 439–451
Esteller M (2000) Epigenetic lesions causing genetic lesions in human cancer. Promoter hypermethylation of DNA reapir genes. Eur J Cancer 36: 2294–2230
Fang S, Jensen JP, Ludwig RL, Vousden KH and Weissman AM (2000) Ubiquitin protein ligase activity of Mdm2: Differential RING finger requirements for ubiquitination and proteasomal targeting of Mdm2 and p53. J Biol Chem 275: 8945–8951
Ferbeyre G, de Stanchina E, Querid E, Baptiste N, Prives C and Lowe SW (2000) PML is induced by oncogenic ras and promotes premature senescence. Genes and Dev 14: 2015–2027
Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, Pandolfi PP, Will H, Schneider C and Del Sal G (2000) Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19: 6185–6195
Ford JM and Hanawalt PC (1995) Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc Natl Acad Sci USA 92: 8876–8880
Foster BA, Coffey HA, Morin MJ and Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507–2510
Freedman DA and Levine AJ (1998) Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 18: 7288–7293
Freedman DA, Wu L and Levine AJ (1999) Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55: 96–107
Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, Jones SN and Ronai Z (1998) JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes and Dev 12: 2658–2663
Gaiddon C, Moorthy NC and Prives C (1999) Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. EMBO J 18: 5609–5621
Garkavtsev I, Grigorian IA, Ossovskaya VS, Chernov MV, Chumakov PM and Gudkov AV (1998) The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature 391: 295–298
Geyer RK, Yu ZK and Maki CG (2000) The MDM2 RING-finger domain is required to promote p53 nuclear export. Nature Cell Biol 2: 569–573
Gostissa M, Hengstermann A, Fogal V, Sandy P, Scheffner M and Del Sal G (1999) Activation of p53 by conjugation to the ubiqutin-like protein SUMO-1. EMBO J 18: 6462–6471
Gottlieb E, Haffner R, von Ruden T, Wagner EF and Oren M (1994) Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3 dependent hematopoietic cells following IL-3 withdrawal. EMBO J 13: 1368–1374
Gotz C, Kartarius S, Scholtes P, Nastainczyk W and Montenarh M (1999) Identification of a CK2 phosphorylation site in mdm2. Eur J Biochem 266: 493–501
Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao ZX, Kumar S, Howley PM and Livingston DM (1998) p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 2: 405–415
Gu W and Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the C-terminal domain. Cell 90: 595–606
Guerra B, Gotz C, Wagner P, Montenarh M and Issinger OG (1997) The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation. Oncogene 14: 2683–2688
Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W and Pandolfi PP (2000) The function of PML on p53-dependent apoptosis. Nature Cell Biol 2: 730–736
Hainaut P and Hollstein M (2000) p53 and human cancer; the first ten thousand mutations. Adv Cancer Res 77: 81–137
Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ (1993) The p21 CDK-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805–816
Haupt Y, Maya R, Kazaz A and Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299
Hay TJ and Meek DW (2000) Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. FEBS Let 478: 183–186
Hermeking H, Lengauer C, Polyak K, He T-C, Zhang L, Thiagalingam S, Kinzler KW and Vogelstein B (1997) 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3–11
Hietanes S, Lain S, Krausz E, Blattner C and Lane DP (2000) Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA 97: 8501–8506
Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida HDL, Elledge SJ and Mak TW (2000) DNA damage-inducible activation of p53 by the checkpoint kinase Chk2. Science 287: 1824–1827
Hollander MC, Sheikh MS, Bulavin DV, Lundgren K, Augeri-Henmueller L, Shehee R, Molinaro TA, Kim KE, Tolosa E, Ashwell JD, Rosenberg MP, Zhan Q, Fernandz-Salguero PM, Morgan WF, Deng CX and Fornace AJ (1999) Genomic instability in Gadd45a-deficient mice. Nature Genet 23: 176–184
Honda R, Tanaka H and Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25–27
Honda R and Yasuda H (1999) Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18: 22–27
Hsieh JK, Chan FS, O'Connor DJ, Mittnacht S, Zhong S and Lu X (1999) RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell 3: 181–193
Hupp TR, Meek DW, Midgley CA and Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71: 875–886
Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH and Kaelin WG (2000) Role for the p53 homolog p73 in E2F1-induced apoptosis. Nature 407: 645–648
Ishida S, Yamashita T, Makaya U and Tokino T (2000) Adenovirus-mediated transfer of p53-related genes induces apoptosis of human cancer cells. Jpn J Cancer Res 91: 174–180
Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E and Yao T-P (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20: 1331–1340
Jackson MW and Berberich SJ (2000) MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol 20: 1001–1007
Jacobs JJ, Keblusek P, Robanus-Maandag E, Kristel P, Lingbeek M, Nederlof PM, van Welsem T, van de Vijver MJ, Koh EY, Daley GQ and van Lohuizen M (2000) Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breat cancers. Nat Genet 26: 291–299
Jacobs JJL, Scheijen B, Voncken J-W, Kieboom K, Berns A and van Lohuizen M (1999) Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes and Dev 13: 2678–2690
Jayaraman L and Prives C (1999) Covalent and noncovalent modifiers of the p53 protein. Cell Mol Life Sci 55: 76–87
Jayaraman L, Murthy KGK, Zhu C, Curran T, Xanthoudakis S and Prives C (1997) Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes and Dev 11: 558–570
Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M and Prives C (1998) High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes and Dev 12: 462–472
Jimenez GS, Nister M, Stommel JM, Beeche M, Barcarse EA, Zhang X-Q, O'Gorman S and Wahl G (2000) A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nature Genet 26: 37–41
Joazeiro CAP and Weissman AW (2000) RING finger proteins: mediators of ubiquitin ligase activity. Cell 102: 549–552
Jones SN, Roe AE, Donehower LA and Bradley A (1995) Rescue of embyonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206–208
Juan L-J, Shia W-J, Chen M-H, Yang W-M, Seto E, Lin Y-S and Wu C-W (2000) Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 275: 20436–20443
Juven-Gershon T, Shifman O, Unger T, Elkeles A, Haupt Y and Oren M (1998) The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol Cell Biol 18: 3974–3982
Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G and Sherr CJ (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649–659
Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF and Sherr CJ (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95: 8292–8297
Kapoor M and Lozano G (1998) Functional activation of p53 via phosphorylation following DNA damage by UV but not γ-irradiation. Proc Natl Acad Sci USA 95: 2834–2837
Kastan MB, Zhan Q, El Deiry W-S, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace, Jr., A-J (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587–597
Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y and Shkedy D (1999) Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DMA damage. Proc Natl Acad Sci USA 96: 14973–14977
Kirch HC, Flaswinkel S, Rumpf H, Brockmann D and Esche H (1999) Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max. Oncogene 18: 2728–2738
Kobet E, Zeng X, Zhu Y, Keller D and Lu H (2000) MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci USA 97: 12547–12552
Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV and Gudkov AV (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733–1737
Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW, Kastan M and Giaccia A (2001) Regulation of p53 by hypoxia; dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21: 1297–1310
Kubbutat MHG and Vousden KH (1997) Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol 17: 460–468
Kubbutat MHG, Jones SN and Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387: 299–303
Kubbutat MHG, Ludwig RL, Levine AJ and Vousden KH (1999) Analysis of the degradation function of Mdm2. Cell Growth and Diff 10: 87–92
Lain S, Midgley C, Sparks A, Lane EB and Lane DP (1999) An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODS. Exp Cell Res 248: 457–472
Lakin ND and Jackson SP (1999) Regulation of p53 in response to DNA damage. Oncogene 18: 7644–7655
Li P-F, Dietz R and von Harsdorf R (1999) p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J 18: 6027–6036
Lin Y and Benchimol S (1995) Cytokines inhibit p53-mediated apoptosis but not p53-mediated Gl arrest. Mol Cell Biol 15: 6045–6054
Lin Y, Ma W and Benchimol S (2000) Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nature Genet 26: 124–127
Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD and Berger SL (1999) p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 19: 1202–1209
Ljungman M (2000) Dial 9-1-1 for p53: Mechanisms of p53 activation by cellular stress. Neoplasia 2: 208–225
Lohrum M and Scheidtmann KH (1996) Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes. Oncogene 13: 2527–2539
Lohrum MAE, Ashcroft M, Kubbutat MHG and Vousden KH (2000) Identification of a cryptic nucleolar localization signal in MDM2. Nature Cell Biol 2: 179–181
Loughran O and La Thangue NB (2000) Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol Cell Biol 20: 2186–2197
Lu W, Pochampally R, Chen L, Traidej M, Wang Y and Chen J (2000) Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene 19: 232–240
Lundberg AS, Hahn WC, Gupta P and Weinberg RA (2000) Genes involved in senescence and immortalization. Curr Opin Cell Biol 12: 705–709
Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, Lozano G, Rosenberg MP and Finlay CA (1997) Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes and Dev 11: 714–725
Luo J, Chen D, Shiloh A and Gu W (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377–381
Ma Y, Yuan R, Meng Q, Goldberg ID, Rosen EM and Fan S (2000) p53-independent down-regulation of Mdm2 in human cancer cells treated with adriamycin. Mol Cell Biol Res Commun 3: 122–128
Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH and Hannon GJ (1999) twist is a potential oncogene that inhibits apoptosis. Genes and Dev 13: 2207–2217
Maheswaran S, Englert C, Bennerr P, Heinrich G and Haber DA (1995) The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes and Dev 9: 2143–2156
Malkin D, Li FP, Strong LC, Fraumini, Jr,, JF Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA and Friend SH (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasias. Science 250: 1233–1238
Marchenko ND, Zaika A and Moll UM (2000) Death signal-induced localization of p53 protein to the mitochondria. J Biol Chem 275: 16202–16212
Marechal V, Elenbaas B, Piette J, Nicolas J-C and Levine AJ (1994) The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol Cell Biol 14: 7414–7420
Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D and Kaelin, Jr., WG (1998) Viral oncoproteins discriminate between p53 homolog p73. Mol Cell Biol 18: 6316–6324
Maya R and Oren M (2000) Unmasking of phosphorylation-sensitive epitopes on p53 and Mdm2 by a simple western-phosphatase procedure. Oncogene 19: 3213–3215
Mayo LD, Turchi JJ and Berberich SJ (1997) Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res 57: 5013–5016
McCormick F (2000) Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015. Semin Cancer Biol 10: 453–459
McKay BC, Ljungman M and Rainbow AJ (1999) Potential roles of p53 in nucleotide excision repair. Cancinog 20: 1389–1396
Meek DW (1999) Mechanisms of switching on p53: a role for covalent modifications. Oncogene 18, 7666–7675
Meyn MS (1999) Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin Genet 55: 289–304
Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT and Lane DP (2000) An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19: 2312–2323
Miyashita T and Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293–299
Momand J, Zambetti GP, George DL and Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237–1245
Montes de Oca Luna R, Wagner DS and Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203–206
Muller S, Berger M, Lehembre F, Seeler JS, Haupt Y and Dejean A (2000) c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem 275: 13321–13329
Muslin AJ and Xing H (2000) 14-3-3 proteins: regulation of subcellular localization by molecular interference. Cell Sig 12: 703–709
Nakano K and Vousden KH (2001) PUMA, a novel pro-apopototic gene, is induced by p53. Mol Cell 7: 683–694
Nakano K, Balint E, Ashcroft M and Vousden KH (2000) A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19: 4283–4289
Nishimori H, Shiratsuchi T, Urano T, Kimura Y, Kiyono K, Tatsumi K, Yoshida S, Ono M, Kuwano M, Nakamura Y and Tokino T (1997) A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 15: 2145–2150
O'Connor DJ and Lu X (2000) Stress signals induce transcriptionally inactive E2F-1 independently of p53 and Rb. Oncogene 19: 2369–2376
Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T and Tanaka N (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053–1058
Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y and Taya Y (2000) p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849–862
Offer H, Zurer I, Banfalvi G, Reh'k M, Falcovitz A, Milyavsky M, Goldfinger N and Rotter V (2001) p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress. Cancer Res 61: 88–96
Ohki R, Nemoto J, Mrasawa H, Oda E, Inazawa J, Tanaka N and Taniguchi T (2000) Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem 275: 22627–22630
Oliner JD, Kinzler KW, Meltzer PS, George DL and Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80–83
Ongkeko WM, Wang XQ, Siu WY, Lau AWS, Yamashita K, Harris AL, Cox LS and Poon RYC (1999) MDM2 and MDMX bind and stabilize the p53-related protein p73. Current Biology 9: 829–832
Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang W-W, Kruzel E and Radinsky R (1995) Wild-type human p53 and a temperature sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15: 3032–3040
Pariat M, Carillo S, Molinari M, Salvat C, Debussche L, Bracco L, Milner J and Piechaczyk M (1997) Proteolysis by calpains: a possible contribution to degradation of p53. Mol Cell Biol 17: 2806–2815
Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP and Pelicci PG (2000) PML regulates p53 acetylation and premature senescence induced by oncogenic ras. Nature 406: 207–210
Perry ME, Mendrysa SM, Saucedo LJ, Tannous P and Holubar M (2000) p76 (MDM2) inhibits the ability of p90 (MDM2) to destabilize p53. J Biol Chem 275: 5733–5738
Phillips AC, Ernst MK, Bates S, Rice NR and Vousden KH (1999) E2F-1 potentiates cell death by blocking anti-apoptotic signaling pathways. Mol Cell 4: 771–781
Pietenpol JA, Tokino T, Thiagaligam S, El-Deiry W, Kinzler KW and Vogelstein B (1994) Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 91: 1998–2002
Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B (1997) A model for p53-induced apoptosis. Nature 389: 300–305
Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee H-W, Cordon-Cardo C and DePinho RA (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713–723
Prabhu NS, Somasundaram K, Satyamoorthy K, Herlyn M and El-Deiry WS (1998) p73β, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int J Oncol 13: 5–9
Prisco M, Hongo A, Rizzo MG, Sacchi A and Baserga R (1997) The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol Cel Biol 17: 1084–1092
Radfar A, Unnikrishnan I, Lee HW, DePinho RA and Rosenberg N (1998) p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. Proc Natl Acad USA 95: 13194–13199
Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC and Perucho M (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967–969
Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, Schlegel U and Reifenberger G (1999) Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 59: 6091–6096
Rodriguez MS, Desterro JMP, Lain S, Midgley CA, Lane DP and Hay RT (1999) SUMO-1 modification activates the transcriptional response of p53. EMBO J 18: 6455–6461
Roth JA, Swisher SG and Meyn RE (1999) p53 tumor suppressor gene therapy for cancer. Oncology 13: 148–154
Ryan KM and Vousden KH (1998) Characterization of structural p53 mutants which show selective defects in apoptosis, but not cell cycle arrest. Mol Cell Biol 18: 3692–3698
Ryan KM, Ernst MK, Rice NR and Vousden KH (2000) Role of NF-kB in p53-mediated programmed cell death. Nature 404: 892–897
Sakaguchi K, Sakamoto H, Lewis MS, Anderson CW, Erickson JW, Appella E and Xie D (1997) Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochem 36: 10117–10124
Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW and Appella E (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes and Dev 12: 2831–2841
Sakaguchi K, Saito S, Higashimoto Y, Roy S, Anderson CW and Appella E (2000) Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a caseine 1-like kinase. Effect on MDM2 binding. J Biol Chem 275: 9278–9283
Scheffner M, Huibregtse JM, Viestra RD and Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495–505
Selivanova G, Iotsova V, Okan I, Fritsche M, Ström M, Groner B, Grafström RC and Wiman KG (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med 3: 632–638
Sengupta S, Vonesch J-L, Waltzinger C, Zheng H and Wasylyck B (2000) Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J 19: 6051–6064
Sharp DA, Kratowicz SA, Sank MJ and George DL (1999) Stabilization of the MDM2 oncogene by interaction with the structurally related MDMX protein. J Biol Chem 274: 38189–38196
Shaw P, Freeman J, Bovey R and Iggo R (1996) Regulation of specific DNA binding by p53: evidence for a role of O-glycosylation and charged residues at the carboxy-terminus. Oncogene 12: 921–930
Sherr CJ and Weber JD (2000) The ARF/p53 pathway. Curr Opin Genet Dev 10: 94–99
Shieh S-Y, Ikeda M, Taya Y and Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325–334
Shieh S-Y, Ahn J, Tamai K, Taya Y and Prives C (2000) The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes and Dev 14: 289–300
Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RCA, van der Houven van Oordt W, Hateboer G, van der Ed AJ and Jochemsen AG (1996) MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 15: 5349–5357
Sigalas I, Calvert AH, Anderson JJ, Neal DE and Lunec J (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nature Med 2: 912–917
Simbulan-Rosenthal CM, Rosenthal DS, Luo R and Smulson ME (1999) Poly(ADP-ribosyl)ation of p53 during apoptosis in human osteosarcoma cells. Cancer Res 59: 190–194
Sionov RV, Moallem E, Berger M, Kazaz A, Gerlitz O, Ben-Neriah Y, Oren M and Haupt Y (1999) c-Abl neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 274: 8371–8374
Smith ML, Chen I-T, Zhan Q, Bae I, Chen C-Y, Gilmer TM, Kastan MB, O'Connor PM and Fornace AJ (1994) Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266: 1376–1380
Smith ML, Ford JM, Hollander MC, Bortnick RA, Amundson SA, Seo YR, Deng CX, Hanawalt PC and Fornace AJ (2000) p53-mediated DNA repair responses to UV irradiation: studies of mouse cells lacking p53, p21 and/or gadd45. Mol Cell Biol 20: 3705–3714
Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW and Lowe SW (1999) Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284: 156–159
Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordón-Cardo C and Lowe SW (2001) Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409: 207–211
Srivistava S, Zou Z, Pirollo K, Blattner W and Chang EH (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumini syndrome. Nature 348: 747–749
Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ and Wahl GM (1999) A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 18: 1660–1672
Stott F, Bates SA, James M, McConnell BB, Starborg M, Brookes S, Palmero I, Hara E, Ryan KM, Vousden KH and Peters G (1998) The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17: 5001–5014
Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H, Taya Y and Imai K (2000) p53-inducible Wip1 phosphotase mediated a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 23: 6517–6526
Takimoto R and El-Deiry WS (2000) Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19: 1735–1743
Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y and Nakamura Y (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404: 42–49
Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A and Ohtsubo M (1999) MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 447: 5–9
Tao W and Levine AJ (1999) Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 96: 3077–3080
Thornborrow EC and Manfredi JJ (1999) One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element. J Biol Chem 274: 33747–33756
Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M and Haupt Y (1999) Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 18: 1805–1814
Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM (1996) Suppression of TNFα induced apoptosis by NF-kB. Science 274: 787–790
Vaziri H, West MD, Allsopp RC, Davison TS, Wu Y-S, Arrowsmith CH, Poirier GG and Benchimol S (1997) ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J 16: 6018–6033
Vogelstein B, Lane D and Levine AJ (2000) Surfing the p53 network. Nature 408: 307–310
Vousden KH (2000) p53: death star. Cell 101: 691–694
Wadgaonkar R and Collins T (1999) Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanisms for inhibition of p53-dependent gene expression. J Biol Chem 274: 13760–13767
Waldman T, Kinzler KW and Vogelstein B (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187–5190
Waldman T, Lengauer C, Kinzler KW and Vogelstein B (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381: 713–716
Wang X, Ohnishi K, Takahashi A and Ohnishi T (1998) Poly(ADP-ribosyl)ation is required for p53-dependent signal transduction induced by radiation. Oncogene 17: 2819–2825
Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O'Connor PM, Fornace AJJ and Harris CC (1999) GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA 96: 3706–3711
Wani MA, Zhu QZ, El-Mahdy M and Wani AA (1999) Influence of p53 tumor suppressor protein in bias of DNA repair and apoptotic response in human cells. Carcinogenesis 20: 765–772
Waterman MJ, Stavridi ES, Waterman JL and Halazonetis TD (1998) ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 19: 175–178
Weber JD, Taylor LJ, Roussel MF, Sherr CJ and Bar-Sagi D (1999) Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biol 1: 20–26
Weber JD, Kuo M-L, Bothner B, DiGiammarino EL, Kriwacki RW, Roussel MF and Sherr CJ (2000) Cooperative signals governing the ARF-Mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol 20: 2517–2528
Wu G, Burns TF, McDonald ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G and El-Deiry WS (1997) KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17: 141–143
Wu H and Lozano G (1994) NF-kappaB activation of p53. A potential mechanism for suppressing cell growth in response to stress. J Biol Chem 269: 20067–20074
Wu L and Levine AJ (1997) Differential Regulation of the p21/WAF-1 and mdm2 genes after high dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol Med 3: 441–451
Wu XW, Bayle JH, Olson D and Levine AJ (1993) The p53 mdm-2 autoregulatory feedback loop. Genes and Dev 7: 1126–1132
Yam CH, Siu WY, Arooz T, Chiu CHS, Lau A, Wang XQ and Poon RYC (1999) MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins. Cancer Res 59: 5075–5078
Yu J, Zhang L, Hwang PM, Kinzler KW and Vogelstein B (2001) PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell In press,
Yu ZK, Geyer RK and Maki CG (2000) MDM2-dependent ubiquitnation of nuclear and cytoplasmic p53. Oncogene 19: 5892–5897
Zaika A, Marchenko N and Moll UM (1999) Cytoplasmically “sequestered” wild type p53 protein is resistant to Mdm2-mediated degradation. J Biol Chem 274: 27474–27480
Zeimet AG, Riha K, Berger J, Widschwendter M, Hermann M, Daxenbichler G and Marth C (2000) New insights into p53 regulation and gene therapy for cancer. Biochem Pharmacol 60: 1153–1163
Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, Kaelin WGJ, Oren M, Chen J and Lu H (1999) MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 19: 3257–3266
Zeng X, Keller D, Wu L and Lu H (2000) UV but not gamma irradiation accelerates p53-induced apopotosis in teratocarcinoma cells by repressing MDM2 transcription. Cancer Res 60: 6184–6188
Zhang W, Lu Q, Xie Z-J and Mellgren RL (1997) Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Try diazomethyl ketone: evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition. Oncogene 14: 255–263
Zhang Y, Xiong Y and Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725–734
Zhou J, Ahn J, Wilson SH and Prives C (2001) A role for p53 in base excision repair. EMBO J 20: 914–923
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Bálint, É., Vousden, K. Activation and activities of the p53 tumour suppressor protein. Br J Cancer 85, 1813–1823 (2001). https://doi.org/10.1054/bjoc.2001.2128
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2128
This article is cited by
-
The Role of p53 in HIV Infection
Current HIV/AIDS Reports (2023)
-
1H, 15N and 13C backbone resonance assignments of the acidic domain of the human MDM2 protein
Biomolecular NMR Assignments (2023)
-
Yeast-based screening of cancer mutations in the DNA damage response protein Mre11 demonstrates importance of conserved capping domain residues
Molecular Biology Reports (2021)
-
Novel Mannich base 3FB3FA8H induces apoptosis by upregulating P53 pathway in neuroblastoma cells
Molecular and Cellular Biochemistry (2020)
-
Response of neuroblastoma cells to RF currents as a function of the signal frequency
BMC Cancer (2019)